JY
PTGX icon

Jeff Yass’s Protagonist Therapeutics PTGX Stock Holding History

Jeff Yass’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.79M Buy
55,400
+18,400
+50% +$1.92M ﹤0.01% 4050
2026
Q1 		$3.9M Buy
37,000
+5,100
+16% +$452K ﹤0.01% 4721
2025
Q4 		$2.79M Sell
31,900
-2,600
-8% -$213K ﹤0.01% 5004
2025
Q3 		$2.29M Sell
34,500
-52,900
-61% -$3.01M ﹤0.01% 5489
2025
Q2 		$4.83M Sell
87,400
-36,800
-30% -$1.77M ﹤0.01% 4029
2025
Q1 		$6.01M Buy
124,200
+34,700
+39% +$1.45M ﹤0.01% 3309
2024
Q4 		$3.45M Buy
89,500
+76,900
+610% +$3.35M ﹤0.01% 4194
2024
Q3 		$567K Sell
12,600
-21,500
-63% -$869K ﹤0.01% 8161
2024
Q2 		$1.18M Sell
34,100
-16,100
-32% -$472K ﹤0.01% 6189
2024
Q1 		$1.45M Buy
50,200
+16,600
+49% +$452K ﹤0.01% 6081
2023
Q4 		$770K Buy
33,600
+1,800
+6% +$31.5K ﹤0.01% 7630
2023
Q3 		$530K Sell
31,800
-187,200
-85% -$3.63M ﹤0.01% 8082
2023
Q2 		$6.05M Buy
219,000
+75,300
+52% +$1.88M ﹤0.01% 3222
2023
Q1 		$3.31M Sell
143,700
-15,700
-10% -$264K ﹤0.01% 4136
2022
Q4 		$1.74M Buy
159,400
+57,800
+57% +$488K ﹤0.01% 4978
2022
Q3 		$856K Buy
101,600
+61,200
+151% +$579K ﹤0.01% 7042
2022
Q2 		$320K Sell
40,400
-9,100
-18% -$110K ﹤0.01% 9411
2022
Q1 		$1.17M Sell
49,500
-207,200
-81% -$5.84M ﹤0.01% 6719
2021
Q4 		$8.78M Sell
256,700
-100,800
-28% -$3.19M ﹤0.01% 2911
2021
Q3 		$6.33M Buy
357,500
+318,400
+814% +$13.6M ﹤0.01% 3547
2021
Q2 		$1.75M Sell
39,100
-4,200
-10% -$139K ﹤0.01% 6225
2021
Q1 		$1.12M Sell
43,300
-1,000
-2% -$25.3K ﹤0.01% 7442
2020
Q4 		$893K Buy
+44,300
New +$953K ﹤0.01% 6971

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Jeff Yass's PTGX Position: Q2 2026 in Review

Jeff Yass reduced its Protagonist Therapeutics (PTGX) stake by 66% in Q2 2026, selling an estimated $11.5M and leaving 57,062 shares worth $6.99M. The position accounts for ﹤0.01% of the portfolio, ranked #3997.

Jeff Yass first reported a position in PTGX in Q4 2018 and has held it in 26 quarters since. The position peaked at $17.7M in Q1 2026. 342 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Jeff Yass held 57,062 shares of Protagonist Therapeutics worth $6.99M as of Q2 2026.
  • Jeff Yass sold 110,514 Protagonist Therapeutics shares in Q2 2026, an estimated $11.5M.
  • Protagonist Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #3997 holding.
  • Jeff Yass first reported a position in Protagonist Therapeutics in Q4 2018 and has held it in 26 quarters since.
  • Jeff Yass's Protagonist Therapeutics position peaked at $17.7M in Q1 2026.
  • 342 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.